Evaluation of some tissue and serum biomarkers in prostatic carcinoma among Egyptian males

Ahmed, Maha; Abd-Elmotelib, Fayeda; Farag, R.; Ziada, Nawal A; Khalifa, Ali

doi:10.1016/s0009-9120(99)00037-5

Cited by 3 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite this problem, it should be remarked that sE-cad levels were higher in patients with high grade tumours (G3 vs. G2 and Gleason score =7 vs. <7). This is in agreement with data from other authors (16)(17)(18), although we did not find any statistically significant correlation.…”

Section: Discussionsupporting

confidence: 93%

“…Values determined in patients were significantly higher than those observed in healthy subjects according to reports by other authors (5,15,16,18,28). After RRP, a significant decrease in E-cad levels was observed.…”

Section: Discussioncontrasting

confidence: 40%

“…E-cad ectodomain shedding determines the release into the body fluids of a soluble 80 kDa E-cad fragment (sE-cad) (12). High sE-cad serum levels are present in cancer patients when compared with those of healthy individuals and they are significantly associated with metastasis, recurrence, and prognosis in some malignancies, including PCa (13)(14)(15)(16)(17)(18). It has been reported that sE-cad is involved in stimulation of invasion in a paracrine manner, in promotion of cell junction disruption and of cell dissemination thereby inducing the migratory phenotype (19).…”

Section: Introductionmentioning

confidence: 99%

“…It has been reported that sE-cad is involved in stimulation of invasion in a paracrine manner, in promotion of cell junction disruption and of cell dissemination thereby inducing the migratory phenotype (19). Moreover, the highest expression levels of sE-cad have been found in patients with metastatic cancers, and high levels at the time of diagnosis are associated with a significant risk of biochemical failure (16)(17)(18) (17). Regarding interleukins (IL), they are pleiotropic cytokines with a wide range of biological activities including immune regulation, hematopoiesis, inflammation and oncogenesis (20).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy

Sica¹

2012

Oncol Rep

View full text Add to dashboard Cite

Abstract. Prostate specific antigen (PSA) is still the best available tumour marker in prostate cancer (PCa), but presents some limits. Therefore, there is a need for novel markers in the detection and management of PCa. The 80-kDa soluble form of E-cadherin (sE-cad) and the cytokine IL-6 are being discussed as supplemental serum markers for PCa. In this study, sE-cad and IL-6 serum levels were determined in patients with pathological localized or locally advanced PCa without any previous treatment. These patients underwent radical retropubic prostatectomy (RRP) in accordance with the EAU Guidelines on Prostate Cancer. The molecules were determined via immunoenzymatic assays in samples collected before and after surgery. Statistical analysis was performed by Student's t-test and Pearson's correlation test. sE-cad levels were 6.0±2.7 and 4.6±2.3 µg/ml, before and after RRP, respectively. A highly statistically significant decrease in sE-cad concentrations after RRP was observed (P<0.0001), in 50/61 patients (82%). sE-cad levels before and after surgery were correlated (Pearson's correlation coefficient, r=0.6993, P<0.0001). sE-cad values detected after surgery were higher in patients with PSA levels >10 ng/ml (P<0.05). sE-cad levels before RRP were significantly higher in patients with G3 tumours compared to those with G2 tumours (P<0.02). Finally, sE-cad concentrations both before and after surgery were higher in tumours with Gleason score =7 compared to those with Gleason score <7 (P<0.002 and P<0.05, respectively). Preliminary data from 20 patients indicated a statistically significant increase in IL-6 levels after RRP (11.2 vs. 7.2 pg/ml, P<0.001). This is the first study on the reduction in sE-cad levels after RRP in PCa patients. Moreover, it shows that preoperative sE-cad concentrations are higher in patients with less differentiated PCa. Promising findings of this pilot study may lead to investigation of sE-cad in a larger study with follow-up.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussioncontrasting

confidence: 40%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy

Sica¹

2012

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…So far, little has been reported about sE-cadherin in connection with PCa. Ahmed et al [ 24 ] investigated its potential as a biomarker in a group of 71 Egyptian males with PCa. In agreement with our findings, significant over-expression of sE-cadherin in the serum of tumor patients, compared to healthy individuals, was observed.…”

Section: Discussionmentioning

confidence: 99%

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

Tsaur

Thurn

Juengel

et al. 2015

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundMeasurement of prostate-specific antigen (PSA) advanced the diagnostic and prognostic potential for prostate cancer (PCa). However, due to PSA’s lack of specificity, novel biomarkers are needed to improve risk assessment and ensure optimal personalized therapy. A set of protein molecules as potential biomarkers was therefore evaluated in serum of PCa patients.MethodsSerum samples from patients undergoing radical prostatectomy (RPE) for biopsy-proven PCa without neoadjuvant treatment were compared to serum samples from healthy subjects. Preliminary screening of 119 proteins in 10 PCa patients and 10 controls was carried out by the Proteome Profiler Antibody Array. Those markers showing distinct differences between patients and controls were then further evaluated by ELISA in the serum of 165 PCa patients and 19 controls. Uni- and multivariate as well as correlation analysis were performed to test the capability of these molecules to detect disease and predict pathological outcome.ResultsScreening showed that soluble (s)E-cadherin, E-selectin, MMP2, MMP9, TIMP1, TIMP2, Galectin and Clusterin warranted further evaluation. sE-Cadherin, TIMP1, Galectin and Clusterin were significantly over- and MMP9 under-expressed in PCa compared to controls. The concentration of sE-cadherin, MMP2 and Clusterin correlated negatively and that of MMP9 and TIMP1 positively with the Gleason Sum at prostatectomy. Only sE-cadherin significantly correlated with the highest Gleason pattern. Compared to serum PSA, sE-cadherin provided an independent and better matching predictive ability for discriminating PCas with an upgrade at RPE and aggressive tumors with a Gleason Sum ≥7.ConclusionssE-cadherin performed most favorably from a large panel of serum proteins in terms of diagnostic and predictive potential in curatively treatable PCa. sE-cadherin merits further investigation as a biomarker for PCa.

show abstract

Comparison of serum prostate specific antigen (PSA), soluble E-cadherin (sE-cad), and inosine monophosphate dehydrogenase-2 (IMPDH-2) as aggressive prostate cancer predictors

Umar,

Mungadi,

Agwu

et al. 2024

Afr J Urol

View full text Add to dashboard Cite

Background This study aimed to compare serum prostate specific antigen (PSA), Soluble E-cadherin (sE-cad), and Inosine Monophosphate Dehydrogenase-2 in predicting prostate cancer aggressiveness by determining their correlations with Gleason score and International Society of Urological Pathology (ISUP) Grade Groups. Methods This was a hospital-based descriptive quantitative cross-sectional study whereby we enrolled 48 newly diagnosed prostate adenocarcinoma patients in the study. Their serum was analysed for PSA, sE-cad, and IMPDH-2. Pearson correlation coefficient was used to test the correlation between the serum sE-cad and Gleason score while Spearman rho correlation coefficient was used for PSA and IMPDH-2. The correlation coefficient (r) was graded as very weak (< 0.3), weak (0.3–0.4), moderate (0.5–0.6), or strong (≥ 0.7), while the magnitude was determined by calculating the coefficient of determination for the respective analysis (R2). The correlation between the biomarkers and the ISUP Grade groups was determined using the Kendall tau correlation coefficient (τ). All levels of statistical significance were set at p < 0.05. Results The mean age of the subjects was 69.4 years. The Means of serum PSA, sE-cad, and IMPDH-2 were 47.2 ng/ml, 136.5 ng/ml, and 89.8 pg/ml respectively. Serum PSA weakly correlated with both Gleason score (r = 0.3, p = 0.04) and ISUP grade groups (τ = 0.3, p = 0.02). The magnitude was 0.097. Similarly, serum sE-cad correlated weakly with both Gleason scores (r = 0.4, p = 0.01), and ISUP Grade Groups (τ = 0.3, p = 0.005). The magnitude was 0.134. However, serum IMPDH-2 neither correlated with Gleason score (r = 0.03, p = 0.86) nor ISUP Grade Groups (τ = 0.004, p = 0.97). Serum sE-cad did not outperform both IMPDH-2 (p = 0.91) or PSA (p = 0.23) in predicting the Gleason score. Conclusions Serum sE-cad best predicted aggressive prostate cancer but did not statistically outperform serum PSA or IMPDH-2. Hence, neither of the three are reliable predictors of aggressive prostate cancer.

show abstract

Evaluation of some tissue and serum biomarkers in prostatic carcinoma among Egyptian males

Cited by 3 publications

References 38 publications

Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy

Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy

sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients

Comparison of serum prostate specific antigen (PSA), soluble E-cadherin (sE-cad), and inosine monophosphate dehydrogenase-2 (IMPDH-2) as aggressive prostate cancer predictors

Contact Info

Product

Resources

About